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Abstract: Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of 
Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. 
Since the discovery of KSHV 20 years ago, there is still no standard treatment and the 
management of virus-associated malignancies remains toxic and incompletely efficacious. 
As the majority of tumor cells are latently infected with KSHV, currently marketed 
antivirals that target the virus lytic cycle have shown inconsistent results in clinic. 
Nevertheless, lytic replication plays a major role in disease progression and virus 
dissemination. Case reports and retrospective studies have pointed out the benefit of 
antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a 
consequence, potent and selective antivirals are needed. This review focuses on the anti-
KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic 
cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and 
compounds that do not target the viral DNA polymerase are being discussed. We also 
cover molecules that target cellular kinases, as well as the potential of new drug targets and 
animal models for antiviral testing. 
Keywords: KSHV; antiviral; nucleoside analog; DNA polymerase inhibitors; lytic cycle; 
ganciclovir; cidofovir; foscarnet 
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1. Introduction 
In 1872, Moritz Kaposi described a rare angiosarcoma that manifested mainly as skin lesions in 
elderly men [1]. More than a century passed between the first description of Kaposi’s sarcoma (KS) 
and the discovery of its etiologic agent, Kaposi’s sarcoma-associated herpesvirus (KSHV), by Chang 
and Moore in 1994 [2]. KS is a neoplasm derived from lymphatic endothelial cells infected with 
KSHV, composed of spindle-shaped cells and inflammatory mononuclear cells [3]. KS is grouped into 
four epidemiological forms: classic, endemic, iatrogenic and AIDS-related [4]. In addition, KSHV has 
been associated with two other diseases, primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) [5]. PEL is a B-cell lymphoma that develops in pleural, pericardial or 
peritoneal cavity, while the B-cell lymphoproliferative disorder MCD is predominantly found in the 
lymph nodes and is characterized by vascular proliferation in the germinal centers [6,7]. 
2. Management of KSHV-Associated Diseases 
There are no standard therapeutic guidelines for the management of KSHV-associated diseases, yet 
the main therapeutic options are discussed below for each disease. The treatment of choice for patients 
with KS depends on several parameters, such as the tumor location and variant of KS, rate of 
progression, distribution of the lesions, severity of the symptoms, and immune competence [8]. 
Therapeutic approaches for classic KS range from no treatment to surgical excision, local delivery of 
chemotherapeutic agents (such as bleomycin, vinblastine, vincristine and alitretinoin), and 
radiotherapy (Table 1) [9]. Management of iatrogenic KS often involves reduction or elimination of 
immunosuppressive therapy with or without local measures, whereas endemic KS is frequently 
responsive to systemic chemotherapy [10,11].  
The current first-line systemic therapy for advanced, progressive acquired immunodeficiency 
syndrome (AIDS)-KS includes liposomal anthracyclines, such as daunorubicin and doxorubicin [12,13]. 
An essential component in the management of human immunodeficiency virus (HIV)-associated KS is 
the control of KS progression with highly active antiretroviral therapy (HAART), which leads to both 
immune reconstitution and control of HIV viremia [12,14,15]. Additional data from HIV cohorts also 
suggested that specific components of HAART might impact the incidence and resolution of KS [16]. 
Several randomized, placebo-controlled trials of high-dose zidovudine for the treatment of HIV 
demonstrated a 36% reduction in risk of developing KS compared with persons receiving placebo alone 
[17]. To date, there are no comprehensive studies conducted to evaluate whether HAART is able to 
inhibit KSHV viral production [18], but it has been shown that zidovudine is a substrate for KSHV 
thymidine kinase (TK) [19].  
In addition, recent research has shown that HIV protease inhibitors, e.g., nelfinavir, have  
anti-angiogenic and anti-tumor properties [20]. Therefore, HAART combinations that contain HIV 
protease inhibitors may be superior for treatment of KS patients than those without [21]. Moreover,  
anti-herpetic agents, such as ganciclovir (GCV), were shown to reduce plasma viral load of KSHV and 
can prevent KS in KSHV-seropositive transplant recipients [9]. Additionally, target-based therapies, 
such as inhibition of angiogenesis, metalloproteinases, and cytokine signaling, may be an effective 
strategy to treat patients with KS that progresses despite chemotherapy and/or HAART [22].  
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PEL has usually been treated with chemotherapy (Table 1), but the prognosis is very poor in 
patients with a median survival of less than six months [23]. Individual case reports documented 
responses to antiviral therapy (GCV, foscarnet (PFA), intracavity cidofovir (CDV, HPMPC)), the 
proteosome inhibitor bortezomib, the immunosuppressive agent rapamycin, the monoclonal antibody 
rituximab (which targets the CD20 protein on the surface of B lymphocytes), and the antitumor 
antibiotic drug bleomycin [24–26].  
In MCD patients, KSHV induces both human IL-6 and virus-encoded IL-6, and, therefore, 
treatment with tocilizumab, an anti-human IL-6 receptor antibody, has led to clinical responses in these  
patients [27]. Recently, siltuximab, a chimeric monoclonal antibody against IL-6, has been developed 
for the treatment of MCD patients showing promising results in a phase I clinical trial [28]. Rituximab 
therapy has been evaluated for the treatment of MCD and up to 70% of patients responded to the 
therapy (Table 1) [24,29,30]. In addition, antiviral therapy with GCV has been reported successful in 
MCD patients, since this disease is associated with active KSHV replication [31].  
Table 1. Treatment modalities of KSHV-related diseases. 
3. Antiviral Therapy for the Treatment and Prevention of KSHV-Related Malignancies 
Inhibition of KSHV lytic phase by antiviral drugs has not shown great efficacy for the treatment of 
KS, primarily due to the small amount of lytic KSHV present in KS tumors [32]. Though, the few cells 
showing lytic replication are known to play a central role in KS tumorigenesis [33]. However, a greater 
proportion of infected cells in PEL and MCD express lytic phase genes (up to 25% in MCD), as 
compared to KS, and, therefore, antiviral agents might be more effective in the treatment of MCD and 
PEL, than of KS [16,33,34]. 
The use of anti-herpes drugs in the protection against the development of AIDS-associated KS has 
been evaluated in a few studies. In 1996, analysis of data from 935 homosexual men with AIDS from 
Treatment 
 
KSHV-related Diseases 
Intensification of HAART  
 
AIDS-KS  
Surgical excision 
 
KS (single skin lesion) 
Radiotherapy 
 
KS 
Immunotherapy Reduction of immunosuppressive therapy KS, PEL and MCD  
 
Anti-CD20 (Rituximab) 
Anti-human IL-6 receptor (Tocilizumab) 
Anti-IL6 chimeric monoclonal antibody 
(Siltuximab) 
MCD  
Chemotherapy Liposomal anthracyclines  KS 
 
CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisone)  
PEL and MCD  
Antiviral drugs (Val)ganciclovir, foscarnet  KS, PEL and MCD 
  Intracavity cidofovir PEL 
Others 
mTOR inhibitor (Rapamycin) 
Proteasome inhibitor (Bortezomib) 
KS, PEL 
PEL 
 
Paclitaxel, anti-angiogenic agents, matrix 
metalloproteinase inhibitors 
KS 
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the Multicenter AIDS Cohort Study showed that ACV did not appear to reduce the risk of KS [35].  
In contrast, among men with cytomegalovirus (CMV) disease, GCV and PFA use were associated 
(although not significant) with a reduced risk of KS. An observational study has also suggested that 
GCV and PFA, but not acyclovir (ACV), may prevent the development of KS in HIV-infected  
patients [35]. Another study performed in the United Kingdom where a total of 3688 HIV patients 
were followed up for a median period of 4.2 years, during which time 598 patients developed KS, also 
indicated that GCV and PFA may have some activity in preventing the occurrence of KS, but that 
ACV had no benefit [36]. In a prospective, randomized, double-blind, placebo-controlled study 
including CMV-infected persons with advanced AIDS stage, prophylactic oral GCV significantly 
reduced the risk of CMV disease but not significant differences between the placebo and GCV groups 
were observed in the 12-month Kaplan-Meir estimates of KS (12% in the placebo group and 8% in the 
GCV group) [37]. The safety and efficacy of valganciclovir (VGCV, the oral prodrug of GCV) on 
HHV-8 replication in the oropharynx in HIV-seropositive and HIV-negative persons who were 
asymptomatically infected with HHV-8 was determined in a randomized, double-blind, placebo-controlled, 
crossover trial. VGCV administered orally once a day proved to be well-tolerated and significantly 
reduced the frequency and quantity of KSHV replication [38].  
Regarding therapy of KS, a pilot study of CDV including seven patients with KS (five patients with 
AIDS-KS and two with classical KS) did not provide proof of principle for the treatment of KS with 
CDV [39]. Despite treatment with CDV (5 mg/kg/dose weekly for two weeks and then every other 
week) all patients had progression of their KS and there was no decrease in the virus load in peripheral 
blood mononuclear cells. Another report described the effects of CDV in two patients with AIDS-KS 
that received the same schedule of treatment for a period of 10 and 12 months [40]. An important 
regression of cutaneous KS lesions was observed after three months of treatment and reactivation of 
new KS lesions was not observed until six and 15 months after the end of the treatment. Treatment of 
classical KS with intralesional injections of CDV for five weeks gave no clinical, histological, 
immunohistological, or virological changes compared with saline-injected lesions [41]. 
KSHV gene expression was studied in CDV-treated and untreated PEL cells following induction to 
lytic replication with TPA (12-O-tetradecanoylphorbol-13-acetate) [42]. This study revealed that the 
expression of genes implicated in the pathogenesis of KS or KS-like tumors, such as vGPCR,  
vIL-6, viral interferon regulatory factor 1 (vIRF-1), and viral macrophage inflammatory protein II 
(vMIP-II), was not inhibited after treatment with CDV. This is likely also true for GCV or PFA, since 
they all block viral DNA replication and inhibiting DNA replication does not prevent expression of 
early genes implicated in viral pathogenesis. This might offer a rationale for the failure of CDV 
therapy in KSHV-related diseases.  
Successful treatments of PEL with antiviral agents, alone or with adjunctive chemotherapy, 
immunotherapy or HAART, have been described to date with both GCV [43,44] and CDV [43,45,46]. 
However, the data on intravenous administration of CDV for treating PEL are limited and also 
controversial. Complete remission has been documented in two HIV-positive patients with PEL when 
CDV was combined with antiretroviral and interferon therapies, while another patient achieved only 
partial remission and died after six months [45,47]. The authors of this case study postulated that the 
concentrations of CDV achieved in the pleural fluid were not high enough when the drug was 
administered intravenously. On the contrary, several studies reported achieving partial or complete 
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remission of PEL in HIV-negative patients with intracavity CDV after conventional chemotherapy 
failure [46,48].  
Additionally, several MCD patients have been successfully treated with GCV [31,49] , whereas 
failures have been reported with CDV [50]. In addition, a pilot study conducted with high dose of 
zidovudine combined with VGCV in patients with symptomatic MCD demonstrated that 12 out of 14 
patients had substantial clinical improvement. However, this study was not randomized and controlled 
trials would be needed to further evaluate the efficacy of zidovudine/VGCV and compare it with other 
approaches [51]. 
The impact of antiviral treatment on KS (i.e., KSHV latently-infected cells) could be potentially 
improved by using combination therapy of antivirals together with lytic inducing agents (leading to 
KSHV reactivation) [33]. The approach of inducing lytic replication of -herpesviruses malignancies 
that employ lytic activation of viruses latently infecting tumors represent a novel strategy of  
anti-neoplastic therapy. This strategy, named lytic induction therapy, has been explored for KSHV, but 
in contrast to Epstein-Barr virus (EBV), has not yet been validated in clinical trials [52]. Agents that 
induce lytic replication include histone deacetylase inhibitors (HDAC) such as valproic acid,  
phorbol esters, calcium ionophores, and NF-kappaB inhibitors [53]. In vitro, valproic acid has been 
shown to significantly induce KSHV lytic cycle in PEL cells, resulting in apoptosis of the tumor  
cells [54]. However, a pilot clinical trial demonstrated that valproic acid was not able to induce KSHV 
lytic replication in patients with AIDS-associated KS on HAART [55]. Further researches are focusing 
on studying more potent lytic inducing agents, such as bortezomib, 5-azacytidine and vorinostat 
(suberanilohydroxamic acid), as well as on increasing the treatment regimens in patients with  
KS [26,56,57]. In addition to bortezomib, the non-tumor-promoting phorbol ester prostratin was also 
shown to induce immediate-early, early and late KSHV gene expression from two lymphoma cell lines 
in vitro, suggesting that both drugs could be used as therapeutic agents for KSHV-associated 
malignancies [58]. Recently, the combination of bortezomib with the HDAC inhibitor vorinostat was 
found to potently reactivate KSHV lytic replication and to induce PEL cell death, resulting in 
significantly prolonged survival of PEL-bearing mice [59]. These findings provide a strong rationale 
for using proteasome/HDAC inhibitor combination for the therapy of PEL. 
4. Inhibitors of KSHV Lytic Replication under Investigation 
Despite the fact that various antiviral agents inhibit KSHV replication in vitro, no drugs are 
currently licensed for the treatment of KSHV-related diseases. From the target perspective, candidate 
inhibitors for treatment of KSHV-related infections can be divided in two groups, (i) compounds that 
act on the viral DNA polymerase and (ii) drugs that do not interact with the viral DNA polymerase. 
The first group of compounds includes nucleoside analogs, acyclic nucleoside phosphonates (ANPs), 
pyrophosphate analogs and non-nucleoside inhibitors. Their anti-KSHV activities are summarized in 
Table 2. The second group of inhibitors targeting viral proteins comprises compounds isolated from plants. 
4.1. DNA Polymerase Inhibitors: Nucleoside Analogs 
Nucleoside analogs that are approved for the treatment of herpesvirus infections, other than KSHV 
and EBV, include ACV, penciclovir (PCV) and GCV and brivudin (BVDU) (Figure 1).  
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Figure 1. Structures of currently approved nucleoside analogs for herpesvirus infections. 
Acyclovir (ACV), penciclovir (PCV), ganciclovir (GCV) are derivatives of the natural 
nucleoside 2’-deoxyguanosine, whereas brivudin (BVDU) is an analog of the natural 
nucleoside 2’-deoxythymidine. 
Nucleoside analogs in their active forms target and inhibit viral DNA polymerases by acting as 
competitive inhibitors of the natural dNTP substrates and/or by incorporation into the growing DNA 
chain where they can terminate DNA elongation. To become active, they require three intracellular 
phosphorylation steps to convert the nucleoside analogs into mono- (MP), di- (DP), and triphosphate 
(TP) forms (Figure 2). The first phosphorylation step is carried out by viral kinases, limiting this step 
to virus-infected cells [60], whereas the two subsequent phosphorylations are performed by cellular 
kinases [deoxyguanosine monophosphate (dGMP) and deoxynucleoside diphosphate (dNDP)] [61].  
The viral TK of herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) and varicella-zoster 
virus (VZV) performs the initial phosphorylation of nucleoside analogs [62]. However, it has been 
demonstrated that KSHV TK has narrow substrate specificity since it recognizes pyrimidine 
derivatives (i.e., BVDU) and not purine derivatives (i.e., ACV and GCV) [63]. However, there is still a 
debate whether purine analogs could be phosphorylated by the KSHV TK to some degree [64]. Purine 
analogs are activated by the virus protein kinase (PK, ORF36) in KSHV-infected cells. KSHV PK is 
the homolog of the UL97 protein kinase encoded by human cytomegalovirus (HCMV), which is 
responsible for the conversion of GCV, and to a lesser extent of ACV, into their monophosphate forms 
in HCMV-infected cells [65].  
BVDU is dependent on the virus-encoded TK and on its associated thymidylate kinase (dTMP) 
activity responsible for the first and second phosphorylations of BVDU and related analogs [66]. 
Previous studies have shown that KSHV and EBV TK also possesses thymidylate kinase  
activity [63,67]. The last phosphorylation step in the activation of BVDU is carried out by the cellular 
(d)NDP kinase. 
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Figure 2. Mechanism of action of viral DNA polymerase inhibitors against KSHV 
replication. Nucleoside analogs require three phosphorylation steps to become active, 
being their conversions to the monophosphate (MP) forms carried out by the viral TK 
(BVDU) or PK (ACV and GCV). Further phosphorylation to the diphosphate (DP) is 
carried out by the viral TK for BVDU or cellular enzymes for ACV and GCV (i.e., dGMP 
kinase). Conversion of these drugs to their triphosphate form (TP) by the nucleoside  
5’-diphosphate (NDP) kinase results in inhibition of viral DNA polymerases because they 
act as competitive inhibitors of the natural substrate and/or as alternative substrates if 
incorporated into the growing DNA chain. ANPs, such as CDV, do not require activation 
by a virus-encoded enzyme to be active; instead, the two phosphorylations are done by 
cellular kinases (pyrimidine nucleoside monophosphate (PNMP) and 5’-diphosphate 
(NDP) kinase). ANP-DPs, recognized by the viral DNA polymerase, will then block DNA 
synthesis. PFA does not require modifications by viral or cellular kinases. PFA binds to the 
pyrophosphate (PPi) exchange site of the viral DNA polymerase and blocks the release of 
pyrophosphate from the terminal nucleoside triphosphate. As a consequence,  
3’-5’-phosphodiester linkage necessary for viral DNA elongation is not possible (adapted 
from [62]). 
Once activated, the nucleoside analogs in their triphosphate forms enter in competition with the 
natural substrates (dGTP or dTTP) for the viral DNA polymerase. They can inhibit the incorporation 
of natural dGTP or dTTP into the viral DNA in elongation or act as an alternate substrate and be 
incorporated into the DNA at its 3’-terminus [68]. Once ACV is incorporated, it cannot be excised by 
the DNA polymerase-associated 3’-5’ exonuclease and it prevents further chain elongation because the 
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3’-hydroxyl group needed for DNA elongation is missing [69]. It has also been demonstrated that 
following incorporation of ACV-TP, the viral polymerase becomes trapped on the terminated DNA 
chain when the next deoxynucleoside triphosphate binds [69]. On the other hand, PCV, GCV and 
BVDU have a 3’-hydroxyl group on its acyclic side chain, allowing limited chain elongation when 
incorporated into the growing DNA strand [69,70]. 
ACV, marketed as Zovirax
®
, represents the first generation of effective anti-herpetic drugs with an 
excellent safety profile and potent activity against HSV and VZV infections [70]. Due to its limited 
oral bioavailability, the valine ester of ACV (VACV, Zelitrex
®
 and Valtrex
®
) was developed and 
proved to be a safe and efficacious prodrug in patients with genital herpes, herpes labialis, and herpes 
zoster [62]. In vitro, ACV shows inhibitory activity against EBV, while several studies have 
consistently reported the weak anti-KSHV properties of ACV (Table 2) [71–76]. PCV (Denavir® and 
Vectavir
®
) and its orally available prodrug, famciclovir (Famvir
®
) are also indicated for the treatment 
of mucocutaneaous HSV-1 and HSV-2 infections, particularly recurrent herpes labialis, and have a 
spectrum of anti-KSHV activity similar to that of ACV [72,77,78]. Among several purine analogs, an 
ACV derivative, (1S’,2R’)-9-[[1’,2’-bis(hydroxymethyl)cycloprop-1-yl]methyl]guanine (A-5021) was 
also shown to lack activity against KSHV, while this drugs was a potent inhibitor of HSV-1, HSV-2, 
VZV, HHV-6 and EBV replication [79]. Since KSHV does not show great sensitivity to ACV, its 
derivative H2G [R-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is also not inhibitory for KSHV 
replication [72].  
GCV (Cymevene
®
 and Cytovene
®
) was the first antiviral agent approved for the treatment of 
HCMV infections in immunocompromised patients and remains the first-line treatment of HCMV 
disease in transplant recipients [62,80]. In addition to HCMV, GCV has demonstrated efficacy against 
HSV, VZV, EBV, and KSHV replication [72–74,76,81]. Several reports have shown the efficacy of 
GCV against KSHV in the PEL cell line BCBL-1 for which the EC50 ranged from 1 µM to 10 µM 
(Table 2). However, major drawbacks of GCV are its significant bone marrow toxicity, its short 
half-life in tissue following oral administration (~5 h) and low bioavailability (~6% for GCV) [82]. 
Oral bioavailability is significantly improved with its L-valyl-ester derivative, namely VGCV 
(Valacyte
®
), to approximately 60% [62]. A structural analog of GCV, S2242 [(1,3-dihydroxy-2-
propoxymethyl)purine], proved to be a more potent inhibitor of KSHV replication than GCV [72,83]. 
In contrast to GCV, S2242 is not phosphorylated by a herpesvirus kinase [84,85]. In fact, the cellular 
deoxyguanosine kinase is responsible for the first phosphorylation step, and subsequently the 
activation of S2242 [83]. However, the development of S2242 was halted due to toxicity [86].  
Cyclopropavir, a methylenecyclopropane nucleoside resembling GCV, is under preclinical 
development for the treatment of HCMV-related infections. It is first phosphorylated by the HCMV 
PK and, under its active triphosphate form, the drug will further inhibit the viral DNA polymerase 
[87,88]. This compound has also shown good antiviral activity against KSHV replication in vitro for 
which the EC50 was 3.8 µM as measured by DNA hybridization assay [89]. The group of Prichard and 
colleagues reported that analogs of this class of compounds bearing 6-alkylthio substitutions had 
inhibitory efficacies comparable to cyclopropavir against KSHV replication in vitro (Table 2) [89].  
The pyrimidine analog, BVDU (Zostex
®
, Brivirac
®
, Zerpex
®
), is a highly selective antiviral agent 
against HSV-1 and VZV replication and is indicated for the treatment of herpes labialis and herpes 
zoster [70] . BVDU has also shown activity against KSHV, albeit its anti-KSHV antiviral activity may 
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be controversial as it varied from 0.9 µM to 24 µM in BCBL-1 cells depending on the report  
(Table 2) [72,73,90–92]. Still, the in vitro antiviral activity of BVDU could not be confirmed in vivo 
against murine γ-herpesvirus (MHV-68) replication in immunocompetent mice [90] and against  
MHV-68-induced mortality in immunocompromised mice [93]. However, BVDU administered orally 
at similar concentrations, is highly effective against HSV-1 and VZV infections in terms of reducing 
virus-induced mortality or diminishing virus titers in infected mice [94,95]. Thus, BVDU does not 
seem to be a suitable candidate drug for potential treatment of KSHV-related diseases.  
Moreover, 2’-exo-methanocarbathymidine [(North)-methanocarbathymidine (N-MCT)], a thymidine 
analog, was identified as a potent drug with in vitro anti-KSHV activity. N-MCT blocked KSHV 
replication at EC50s 5- to 10-fold lower than those of CDV and GCV, without notable cytotoxicity 
[96]. However, the in vivo antiviral efficacy was not investigated. Additionally, despite the higher 
in vivo (MHV-68 mouse model) antiviral efficacy of two thionucleoside derivatives, KAY-2-41 and 
KAH-39-149, as compared to HDVD, these molecules were active in vitro against EBV but not 
against KSHV [97].  
While the EC50s of zidovudine and stavudine have not been reported, these anti-HIV nucleoside 
reverse transcriptase inhibitors have been shown to be substrates of γ-herpesvirus TK, which 
efficiently converts them to their monophosphate forms [19,63].  
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Table 2. Anti-KSHV activity of viral DNA polymerase inhibitors. 
Class Subclass Abbreviation Drug Name 
EC50 
Range 
(µM) 
a
 
Stage of 
Development 
d
 
Refs. 
Nucleoside 
analogs 
Purine analogs 
ACV Acyclovir 26–138 Cohort study [35,36,72–75,90]  
PCV Penciclovir 43  In vitro [72] 
A-5021 
(1S,2R)-9-[[1,2-bis(hydroxymethyl)  
cycloprop-1yl]methyl]guanine 
75 In vitro [79] 
H2G Omaciclovir 42 In vitro [72] 
GCV Ganciclovir 1.0–10 
Randomized, 
controlled trial 
(with VGCV) 
[31,38,72–75,90] 
S2242 
2-Amino-7-[(1,3-dihydroxy-2-propoxy)-
methyl]purine 
0.1 In vitro [72] 
Methylenecyclopropane 
nucleosides 
CPV Cyclopropavir 3.8 b In vitro [89] 
 
6-Alkoxy-substituted derivatives 1.8–3.5 b In vitro [89] 
 
6-Alkylthio-substituted derivatives 1.9–7.3 b In vitro [89] 
Pyrimidine analogs 
AZT Zidovudine 
 
Randomized trial [17] 
BVDU Brivudine 0.9–24 In vivo [72,73,90] 
N-MCT (North)-methanocarbathymidine 0.08 In vitro [96] 
L-dioxolane uracil 
analog 
HDVD 
1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxolan-4-
yl]5-vinylpyrimidine-2,4(1H,3H)-dione 
0.09 In vivo [90] 
Thiothymidine analogs 
KAY-2-41 1-methyl substituted 4-thiothymidine ≥130 In vivo [97] 
KAH-39-149 4-azido substituted 4-thiothymidine >200 In vivo [97] 
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Table 2. Cont. 
Class Subclass Abbreviation Drug Name 
EC50 Range 
(µM) 
a
 
Stage of 
Development 
d
 
Refs. 
Acyclic nucleoside 
phosphonates 
HPMP derivatives 
HPMPC, CDV Cidofovir 0.3–6.3 Pilot study [39,46,72–75,90] 
CMX001 Brincidofovir 0.7 In vitro [98] 
HPMP-5-azaC 
1-(S)-[3-hydroxy-2-(phosphonomethoxy)-
propyl]-5-azacytosine 
0.7 In vivo [98] 
HPMPA 
(S)-9-[3-hydroxy-2-(phosphonomethoxy)-
propyl]adenine 
0.7 In vitro [72,98] 
HPMPDAP 
(S)-9-[3-hydroxy-2-(phosphonomethoxy)-
propyl]-2,6-diaminopurine 
0.9 In vitro [98] 
HPMPO-DAPy 
(R)-(2,4-diamino-3-hydroxy-6-[2-(phosphono-
methoxy)propoxy])- pyrimidine 
5.1 In vitro [98] 
PME derivatives 
PMEA Adefovir 18–44 In vitro [72,73,75,98] 
PMEDAP 
(9-[2-(phosphonomethoxy)ethyl]-2,6-diamino-
purine 
16 In vitro [98] 
PMEO-DAPy 
2,4-diamino-6-[2-(phosphono-
methoxy)ethoxy]-pyrimidine 
12 In vitro [98] 
PMP derivatives PMPA Tenofovir >150 In vitro Our unpublished data 
Pyrophosphate 
analog 
 PFA Foscarnet sodium  34–39 Cohort study [35,36,74,75] 
Non-nucleoside 
inhibitors 
4-oxo-
dihydroquinolines 
183792, 529311, 
568561, 570886  
1.9–11.1 c In vitro [99] 
Pyrimidoquinoline 
analog 
NSC 373989 
(5-((3-(dimethylamino)propyl)amino)  
-3,10-dimethy-lpyrimido[4,5-b]  
quinoline-2,4(3H,-10H)-dione) 
1.9 In vitro [100] 
a Concentration required to reduces KSHV DNA synthesis in TPA-stimulated BCBL-1 cells by 50% measured by real-time qPCR. The values are the range of the mean 
EC50s of independent experiments as published in the original reports; 
b EC50 measured by flow cytometry; 
c EC50 measured by DNA hybridization assay.  
d Antiviral drug efficacy was evaluated in vitro, in vivo (MHV-68 mouse model) or in patients (cohort study, pilot study of randomized clinical trials).  
HPMP, 3-hydroxy-2-(phosphonomethoxy)propyl; PME, 2-(phosphonomethoxy)ethyl; PMP, 2-(phosphonomethoxy)propyl. 
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4.2. DNA Polymerase Inhibitors: Acyclic Nucleoside Phosphonates 
The first ANP to be accredited with broad-spectrum antiviral activity against DNA viruses was  
(S)-9-(3-hydroxy-2-phosphonomethoxy-propyl)adenine or HPMPA [101]. In this nucleotide analog, 
the phosphate linkage (P-O-C) was replaced by the phosphonate (P-C-O) linkage, which was critical 
for the observed biological activity [102]. Subsequently, CDV was described as an antiviral agent 
active against HCMV and other DNA viruses [64]. In 1996, CDV was licensed for clinical use, under 
the trade name of Vistide
®
, for the treatment of HCMV retinitis in AIDS patients [68]. CDV is 
administered intravenously with the concomitant oral administration of probenecid, in order to block 
the drug uptake by the organic anion transporter in the proximal renal tubular cells that is responsible 
for the drug-related nephrotoxicity [102].  
HPMPA and CDV (HPMPC) are ANPs classified as ‘HPMP’ (3-hydroxy-2-phosphonomethoxypropyl) 
derivatives, and differ from ‘PME’ (2-phosphonomethoxyethyl) derivatives, represented by adefovir  
(9-(2-phosphonomethoxyethyl) adenine, PMEA), according to their spectrum of antiviral activity 
(Figure 3) [62]. Adefovir was reported as an antiviral agent inhibiting Herpesviridae, Hepadnaviridae, 
and Retroviridae [68;101]. This drug was implemented for the treatment of chronic hepatitis  
B under the trade name of Hepsera
®
. PMPA or tenofovir is the representative of the ‘PMP’  
(2-phosphonomethoxypropyl) derivatives of ANPs and has an antiviral spectrum restricted to 
Hepadnaviridae and Retroviridae [68]. The anti-HIV properties of tenofovir were first described in 
1993 [101], and eight years later, the compound was licensed for clinical use for the treatment of HIV 
infections, under the trade name of Viread
®
 [103]. Meanwhile, tenofovir in its oral prodrug form, 
tenofovir disoproxil fumarate, has become one of the cornerstones for anti-HIV therapy [104]. 
Recently, Hepsera
®
 has been largely replaced by tenofovir, since the drug is approximately 30-times 
more potent against hepatitis B virus. 
To accomplish their antiviral action, ANPs, must be first phosphorylated to their monophosphate 
form (MP) and, subsequently, to their diphosphate form (DP), which can be considered as the active 
metabolite that will finally interact with the viral DNA polymerase (Figure 2) [105]. These two 
phosphorylation steps are carried out by cellular enzymes. Of note, the intracellular phosphorylation of 
ANPs is thus independent of the herpesvirus-encoded TK or PK [68]. At the viral DNA polymerase 
level, the diphosphate form acts as a competitive inhibitor or alternate substrate with respect to the 
natural nucleoside, e.g., 2’-deoxycytidine-5’-triphosphate (dCTP) for CDV-DP, whereas the 
mechanism of action of adefovir is similar to that of CDV the integration of one molecule of adefovir 
at the 3’-end of the growing DNA chain terminates further chain elongation. On the other hand, CDV 
requires two consecutive (‘tandem’) incorporations to efficiently terminate DNA elongation by HCMV 
DNA polymerase [104]. 
As shown specifically for CDV, this compound offers a much longer antiviral response (several 
days) than nucleoside analogs, such as ACV, for which the antiviral response lasts for only a few  
hours [104,106] The prolonged antiviral action of CDV can be attributed to the long half-life of the 
CDV metabolites (CDV-MP, CDV-DP, and CDV phosphate-choline adduct) that are formed 
intracellular following uptake of CDV by the cells [107]. In particular the CDV phosphate-choline 
adduct serves as intracellular storage of CDV, since its intracellular half-life is 48 h [108]. 
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A great deal of attention was given to the development of HPMPA analogs to improve its 
pharmacokinetic profile [109]. Promising anti-DNA virus effects were found for the 2,6-diaminopurine 
counterpart of HPMPA (i.e., HPMPDAP) and PMEA (i.e., PMEDAP) (Figure 3) [109]. The activity of  
HPMP-derivatives against DNA viruses is generally higher compared to their counterparts in the  
PME-series [110]. This was also seen against KSHV for which HPMP-derivatives were 10- to 100-fold 
more inhibitory than PME-derivatives (Table 2).  
A second generation of ANPs has been described including the 6-[2-phosphono-methoxy)alkoxy]-
2,4-diaminopyrimidines (DAPy). These compounds fall into two categories with as prototypes  
(R)-HPMPO-DAPy and PMEO-DAPy (Figure 3) [109]. The anti-DNA virus activity of  
(R)-HPMPO-DAPy is similar to that of CDV. Nevertheless, its inhibitory activity was five-fold less 
pronounced against KSHV than CDV (Table 2) [98].  
A new class of promising antiviral compounds came with the discovery of ANPs bearing a triazine 
ring, especially 5-azacytosine as a base component [111]. The 5-azacytosine analog of CDV,  
i.e., 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC) (Figure 3), 
showed similar or higher anti-herpetic activity, including anti-KSHV activity, as compared to CDV. 
However, it remains to be investigated whether CDV derivatives, such as HPMP-5-azaC, would be 
more efficacious than CDV in the treatment of KSHV infections.  
 
Figure 3. Structures of ANPs that exhibit anti-herpetic activity. Cidofovir (CDV, HPMPC), 
HPMPA and adefovir (PMEA) belong together with (S)-HPMPDAP and PMEDAP to the first 
generation of ANPs. (R)-HPMPO-DAPy and PMEO-DAPy belong to the second 
generation of ANPs, and HPMP-5-azaC is a molecule of the third generation of ANPs. 
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In addition to the dose-dependent nephrotoxicity of CDV, another major disadvantage that has 
restrained its use is its low oral bioavailability, due to the presence of the phosphonate group [61]. In 
order to achieve better oral bioavailability, the phosphonate group of the drug can be transformed to a 
phosphonic ester or amidate, which is enzymatically cleaved to the parent drug after passing the 
intestinal barrier, or inside the cells [112]. A considerable number of ANP prodrugs have been 
evaluated, but only a few of them passed preclinical studies. Additionally, lipophilic esters constitute 
an important class of phosphate and phosphonate prodrugs [112].  
Particularly, the hexadecyloxypropyl (HDP) prodrug of CDV or CMX001 (brincidofovir) has 
shown promising results and is currently being developed as prophylactic and preemptive therapy of 
viral DNA infections [113]. A pharmacokinetic and safety study in humans reported that oral 
administration of CMX001 at different doses are well tolerated, with no dose-limiting toxicity, 
particularly, no nephrotoxicity or myelotoxicity, which are the dose-limiting toxicities of CDV or GCV, 
respectively [114]. In addition, CMX001 given orally at a dose of 100 mg to patients that received 
allogeneic hematopoietic-cell transplantation was shown to be well tolerated (i.e., diarrhea was the 
only dose limiting adverse effect) and effective (i.e., it reduced the incidence of HCMV events in these 
patients) [115]. In our studies, KSHV was similarly sensitive to CMX001 or CDV in BCBL-1 cells 
with EC50 values of 0.7 µM and 1.3 µM, respectively (Table 2) [98]. 
4.3. DNA Polymerase Inhibitors: Pyrophosphate Analogs 
Phosphonoacetic acid and phosphonoformic acid are pyrophosphate analogs and non-competitive 
inhibitors of viral DNA polymerases by binding to the pyrophosphate-binding site of the enzyme.  
Hence, these compounds block the release of the pyrophosphate from the terminal nucleoside 
triphosphate added onto the growing DNA chain (Figure 2) [116]. PFA, the trisodium salt of 
phosphonoformic acid (foscarnet), is only available as an intravenous preparation and can cause 
nephrotoxicity and significant electrolyte disturbances [70]. PFA can be considered as a second-line 
therapy and its use is reserved to HSV, VZV, and HCMV patients that have failed ACV or GCV 
therapy due to viral resistance or that cannot be treated with GCV due to side effects of the drug [62]. 
PFA has been used as antiviral for the treatment of KSHV and, despite its lower activity against KSHV 
replication in vitro compared to GCV and CDV, this drug has shown efficacy in KS patients [35,36]. 
4.4. DNA Polymerase Inhibitors: Non-Nucleoside Analogs 
The 4-oxo-dihydroquinolines derivatives have been reported to have activity against most 
herpesviruses, but not against other DNA or RNA viruses. They were found to inhibit the polymerases 
of HSV, VZV, CMV, EBV and KSHV in vitro, and were shown active against a variety of ACV-,  
GCV-, and PFA-resistant HSV and HCMV mutants [99]. By means of flow cytometry, the antiviral 
activity (EC50 values) of four 4-oxo-dihydroquinolines against KSHV were calculated and ranged  
from 1.9 µM to 11 µM (Table 2) [99]. 
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4.5. Non-DNA Polymerase Inhibitors that Target Viral DNA Synthesis 
KSHV encodes for its own DNA polymerase processivity factor, which is required for lytic viral 
replication and allows the viral DNA polymerase to synthesize extended stretches of DNA without 
dissociating from the template [117]. The highly specific interaction between the polymerase and the 
processivity factor may be effectively targeted by small molecules to inhibit (i) the enzymatic activity 
of the polymerase, (ii) the interaction between the two proteins or (iii) the function of the processivity 
factor itself. Dorjsuren and colleagues employed an in vitro assay to screen compounds inhibiting 
KSHV DNA synthesis through targeting the viral DNA polymerase/processivity factor complex [100].  
Of 18 active compounds examined, NSC 373989 was shown to specifically block lytic KSHV DNA 
replication in phorbol-12-myristate-13-acetate (PMA)-stimulated KSHV-infected BCBL-1 cells  
(Table 2) [100]. The active compounds have structures similar to various classes of topoisomerase II 
inhibitors, and these results suggested that certain agents may serve as dual inhibitors of human DNA 
topoisomerase II as well as of KSHV DNA synthesis [100,117]. For example, (+)-Rutamarin,  
a topoisomerase II inhibitor isolated from plants, such as Ruta graveolens L, was also found to 
selectively inhibit KSHV replication [118]. 
4.6. Other Inhibitors of KSHV Replication 
A number of compounds purified from plants are known to inhibit KSHV replication. For instance, 
angelicin, isolated from the seeds of Psoralea corylifolia, is able to inhibit lytic replication of  
γ-herpesviruses during the early stage of de novo infection and/or reactivation [119]. Other drugs 
inhibit the immediately-early Rta promoter of KSHV, or alter the interaction of cellular transcription 
factors with Rta. They include resveratrol (a non-flavonoid polyphenol present in Polygonum 
cuspidatum) and the major cannabinoid compound of marijuana, delta-9 tetrahydrocannabinol 
[120,121].  
Zhang and colleagues have demonstrated that inhibition of KSHV replication could be achieved by 
the use of phosphorodiamidate morpholin oligomers (PMO) which are short single-stranded DNA 
oligomers with a modified backbone conferring resistance to nucleases [122]. In this study, Rta 
(KSHV replication and transcription activator) and LANA (latency-associated nuclear antigen) 
mRNAs were targeted by antisense peptide-conjugated PMO in PEL cells, resulting is a significant 
decrease in viral DNA levels as well as in the expression of several KSHV early and late genes. 
Herpesviruses express a structurally and functionally conserved dimeric protease required for capsid 
assembly during lytic replication. Herpesvirus proteases do not resemble to any known protease fold 
pattern and are thus classified into a separate family of serine proteases [123]. Initial attempts to inhibit 
herpesvirus proteases targeted the active site of the enzyme, relying heavily on chemical structures for 
covalent inhibition and/or peptidomimetic scaffolds. Specifically targeting the active site of 
herpesvirus proteases have not yet result in pharmacologically viable lead compounds despite some  
in vitro success [124–126]. Craik’s group reported on a small molecule, DD2 (a benzyl-substituted  
4-(pyridine-2-amido) benzoic acid), able to disrupt dimerization of KSHV protease by trapping an 
inactive monomeric conformation [127,128]. Two DD2 analogues generated through carboxylate 
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biosteric replacement were shown to inhibit proteases of all three herpesvirus subfamilies (i.e., α, β, 
and γ herpesvirinae) [129].  
 
4.7. Potential Novel Drug Targets in KSHV 
Nucleoside analogs are the leading compounds for treating or suppressing herpesvirus infections for 
more than 50 years now. ACV, PCV and their orally bioavailable prodrugs may not be fully effective, 
but they have been remarkably free from any toxic side-effects. While it will be very difficult for new 
compounds to match these favorable properties, not only novel potential viral targets are being 
explored as therapy for herpesvirus infections, including immediately-early viral proteins, the viral  
helicase-primase and the viral terminase, but also cellular proteins that are important for viral 
replication. While several studies have provided proof-of-principle that helicase-primase and terminase 
inhibitors can be effective antiviral against α- and β-herpesviruses in cell culture and in humans [130–132], 
these new viral targets have not yet been explored for γ-herpesviruses, such as KSHV.  
5. Cellular Targets 
There is an abundance of evidence that host cell protein kinases, and the downstream pathways that 
they control, play a critical role in herpesvirus infection [133]. Inhibitors that target these host proteins 
might act as antiviral agents, yet, the risk for cytotoxicity and side effects increases by targeting host 
protein kinases [134]. Suppression of virus replication by a number of small-molecule inhibitors of 
cellular protein kinases has been demonstrated in vitro and several inhibitors have been incorporated 
into clinical trials examining their efficacies for the treatment of cancers [133]. Cellular 
serine/threonine protein kinases, which play an important role during the course of a KSHV infection, 
are mTOR, cyclic-dependent kinases, casein kinase 2, p90 ribosomal S6 kinases and PI3K, as well as 
tyrosine kinases, such as vascular-endothelial growth factor receptor, ephrin A2 and platelet-derived 
growth factor receptors [133]. Rapamycin, an mTOR inhibitor, was shown to prevent and induce 
regression of KS by inhibiting the expression of immediately-early proteins (Zta and Rta) of 
KSHV [135]. Dasatinib, an ATP-competitive tyrosine kinase inhibitor that inhibits multiple tyrosine 
kinases including EphA2, significantly reduces KSHV infection when cells are pretreated [133]. 
Because ephrin A2 functions as a cellular receptor for KSHV infection of endothelial cells, inhibitors 
of this tyrosine kinase may show promise as anti-KSHV agents. 
6. Animal Models for Antiviral Efficacy Evaluation 
MHV-68 infection in immunocompetent (BALB/c) mice has been well studied as an animal model 
for addressing fundamental aspects of KSHV pathogenesis and/or immunity [136–138]. This mouse 
model proved to be adequate for vaccination studies and for the investigation of strategies that 
modulate the tumorigenicity of virus-infected cells [139].  
Infection of mice with murine γ-herpesvirus 68 (MHV-68) has been exploited as an experimental 
model to explore proof-of-principle vaccination strategies, such as MHV-68 subunit vaccines targeting 
lytic and latency-associated viral proteins, heat-inactivated MHV-68 virions and MHV-68  
replication-deficient viruses. These vaccines were able to reduce the level of MHV-68 acute infection, 
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but had little impact on long-term latency establishment [140–151]. Developing a therapeutic vaccine 
to increase the immune control of KSHV lytic replication and to decrease the KSHV viral load in 
people already infected may reduce the risk of KS and even virus shedding and transmission [152]. 
Since disease incidence in the majority of KSHV-infected people is low, scientific interests and efforts 
to develop a KSHV vaccine have been limited. Another major obstacle is the lack of an amenable 
animal model to evaluate the protective effects [153]. However, the access to a KSHV vaccine would 
have an impact on people that are at high risk of developing tumors, such as in HIV patients, 
immunosuppressed individuals, or for persons living in endemic African areas [153].  
Additionally, the MHV-68 mouse model is particularly useful for the evaluation of the efficacy of 
antiviral agents that target the viral lytic cycle, since viral replication occurs in the lung of infected 
mice. Previously, distinct endpoints have been used to evaluate the efficacy of antiviral agents in vivo, 
such as mortality in MHV-68 immunocompromised mice [93] or inhibition of viral replication in lungs 
of immunocompetent mice [154].  
Different ways have been used to set up KSHV infection in mice. In one model, purified virus is 
injected intravenously to NOD/SCID mice with severe combined immunodeficiency affecting T- and 
B-lymphocyte development as well as with Natural Killer (NK) cell, macrophage and granulocyte 
numbers and function reduced [155]. This model is suited to evaluate longitudinal patterns of viral 
gene expression, cell tropism and immune responses. Some NOD/SCID mice implanted with 
functional human hematopoietic tissue grafts (NOD/SCID-hu) were shown to produce human 
KSHV-specific antibodies [155]. Furthermore, GCV treatment of these chimeric mice at the time of 
inoculation led to prolonged but reversible suppression of viral DNA and RNA levels. A second model 
used NOD/SCID mice reconstituted with KSHV-infected CD34
+
 hematopoietic progenitor cells (HPC) 
where it was shown that the virus establishes persistent infection in NOD/SCID mice and disseminated 
following differentiation of infected HPCs into the B-cell and monocytes linkages [156].  
Growth of PEL derived cells lines as xenografts in immune deficient mice has been used to study 
the in vivo effects of therapeutic strategies for KSHV-associated malignancies [157–160]. A concern 
of this xenograft model is whether they entirely reflect clinical presentations of KSHV PEL. A recent 
study using a PEL xenograft model by intraperitoneal injection of KSHV PEL cells into the peritoneal 
cavity of NOD/SCID mice found that these animals not only developed massive ascites but also single 
or multiple solid tumors on various tissues in ~70%–80% of animals. Although this xenograft model 
can be used for the study of effusion and solid lymphoma observed in patients, tumor cells grown  
in vivo displayed unique features (including viral lytic gene expression profile, rate of solid tumor 
development and tumor microenvironment) to those passed in vitro [161]. 
7. Conclusions 
Since the discovery of KSHV 20 years ago, little progress has been made towards therapies directed 
against this oncogenic virus. In the absence of molecules targeting viral latency and FDA-approved 
antiviral agents for the treatment of KSHV infections, few compounds have been evaluated, mostly  
in vitro, and all targeting the viral DNA polymerase. Previously, GCV was shown to be the most 
effective drug among the marketed antiviral agents for the treatment of KS patients. In contrast to 
GCV, other PK-dependent drugs, such as ACV, PCV, H2G and A-5021, showed weak or no 
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anti-KSHV activity, while TK-dependent drugs, such as HDVD, may be suitable drug candidates. 
Most importantly, because of the unclear role of antiviral therapies targeting lytic phase in the 
prevention or treatment of KSHV-induced diseases, randomized controlled clinical trials are needed to 
determine their true efficacy in different clinical settings. Furthermore, it would be of interest to 
investigate the role and potential of novel ANPs in the treatment of KSHV infections, since CDV 
therapy has shown unclear outcomes in patients. Finally, more efforts should be invested to examine 
the potential of non-nucleoside inhibitors against KSHV replication, as well as drugs that target viral 
proteins other than the viral DNA polymerase, since this proof-of-principle has been shown beneficial 
for other herpesviruses, such as HSV and HCMV.  
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